Orelabrutinib
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Orelabrutinib
- Molecular weight
- 427.5
- Structure (SMILES)
- C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)n2)CC1
- innobruka
- Innobruka
- icp 022
- Icp-022
- ICP-022
- icp022
- ICP022
- orelabrutinib
- Orelabrutinib
- Orelabrutinib (High Dose)
- Orelabrutinib (ICP-022)
- Orelabrutinib (Low Dose)
- orelabrutinib [INN]
- ORELABRUTINIB [USAN]
- Orelabrutinib [WHO-DD]
- Orelabrutinib High dose
- orelabrutinib inn
- Orelabrutinib Low dose
- Orelabrutinib Oral Tablet
- Orelabrutinib tablet
- Orelabrutinib Tablets
- orelabrutinib usan
- orelabrutinib who dd
- Orelabrutinib( higher dose)
- Orelabrutinib( lower dose)
- ATC classification codes
- L01EL04
Sources for recorded values
- CAS registry numbers
- 1655504-04-3
- ChEMBL ID
- CHEMBL4650321
- InChIKey
- MZPVEMOYADUARK-UHFFFAOYSA-N
- PubChem compound IDs
- 91667513
- FDA ingredient codes (UNII)
- WJA5UO9E10
- Patents
- 0
- Designations
- 2
- First in class
- No
- Fast track
- No
- Breakthrough designation
- Yes
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- orelabrutinib
- Type
- Synthetic organic
- Drug name stem
- -tinib
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Bruton tyrosine kinase
- Gene symbol
- BTK
- Protein identifier
- Q06187
- Median affinity
- 8.36
- Affinity units
- pIC50
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
- Action type
- Inhibitor
- Target
- Tyrosine-protein kinase BTK
- Protein identifier
- Q06187
Open Targets mechanisms
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
- Action type
- Inhibitor
- Target
- Tyrosine-protein kinase BTK
- Condition
- Leukemia, Lymphocytic, Chronic, B-Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000095
- Subject identifier
- D015451
- Condition
- Lymphoma, Follicular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000096
- Subject identifier
- D008224
- Condition
- Hodgkin Disease
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Lymphoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Multiple Sclerosis, Relapsing-Remitting
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003929
- Subject identifier
- D020529
- Condition
- Purpura, Thrombocytopenic, Idiopathic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007160
- Subject identifier
- D016553
- Condition
- Waldenstrom Macroglobulinemia
- Highest recorded phase
- 2
- Condition identifier
- EFO:0009441
- Subject identifier
- D008258
- Condition
- Lymphoma, B-Cell, Marginal Zone
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000630
- Subject identifier
- D018442
- Condition
- Lymphoma, Mantle-Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001469
- Subject identifier
- D020522
- Condition
- Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Lupus Erythematosus, Systemic
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007915
- Subject identifier
- D008180
- Condition
- Lymphoma, Follicular
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0018906
- Subject identifier
- D008224
- Condition identifier
- EFO_0000095
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000096
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000191
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000403
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003929
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004256
- Condition identifier
- EFO_0007160
- Highest recorded phase
- 3
- Condition identifier
- EFO_0008522
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009441
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000157
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000630
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001469
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001938
- Condition identifier
- MONDO_0002083
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002571
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0003864
- Condition identifier
- MONDO_0004948
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004949
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004992
- Condition identifier
- MONDO_0005070
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005301
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0007650
- Highest recorded phase
- 2
And 13 more, listed on the interactive page.
- Event
- anaemia
- Reports
- 9
- Reporting signal score
- 22.2936
- Event
- hypoalbuminaemia
- Reports
- 2
- Reporting signal score
- 7.95082
- Event
- hypokalaemia
- Reports
- 8
- Reporting signal score
- 29.4367
- Event
- myelosuppression
- Reports
- 4
- Reporting signal score
- 17.2044
- Event
- neutropenia
- Reports
- 7
- Reporting signal score
- 17.2305
- Event
- neutrophil count decreased
- Reports
- 5
- Reporting signal score
- 16.6713
- Event
- pneumonia
- Reports
- 7
- Reporting signal score
- 14.3736
- Event
- thrombocytopenia
- Reports
- 5
- Reporting signal score
- 10.9802
- NCT03493217
- NCT04578613
- NCT05322733
- NCT05491044
- NCT05918276
- NCT06476899
- NCT03494179
- NCT05051891
- NCT05076097
- NCT05978739
- NCT06363994
- NCT03797456
- NCT06082102
- NCT04014205
- NCT06378138
- NCT04304040
- NCT05014100
- NCT05926427
- NCT04305197
- NCT05688696
- NCT04438005
- NCT05234684
- NCT05351346
- NCT05381506
- NCT05498259
And 9 more, listed on the interactive page.
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 1
- Polar surface area
- 85.52
- Calculated partition coefficient (ALogP)
- 4.53
- Calculated partition coefficient (XLogP)
- 3.6
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 6
- Heavy atoms
- 32
- Molecular formula
- C26H25N3O3
- Monoisotopic mass
- 427.18959167
- Natural product
- No
- Recorded assays
- 128
- Active assays
- 9
Active assay types
- Confirmatory
Related records
Trials (139)
- A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）
- A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP
- A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL
- A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide
- A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
- A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa
- A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma
- A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis
- A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
- A Phase I Study of ICP-022 in Healthy Subjects
- A Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops
- A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy
- A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
- A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
- A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
- A Study of ICP-022 in Patients With R/R DLBCL
- A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)
- A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia
- A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma
- A Study of OLR in First-line Treatment of Mantle Cell Lymphoma
In development for (18)
- Autoimmune thrombocytopenic purpura Phase 2
- B-cell chronic lymphocytic leukemia Phase 3
- Cancer Phase 3
- Diffuse large B-cell lymphoma Phase 3
- Follicular lymphoma Phase 2
- Hodgkins lymphoma Phase 1
- Liver disorder Phase 1
- Lymphoma Phase 2
- MALT lymphoma Phase 2
- Mantle cell lymphoma Phase 3
- Marginal zone lymphoma Phase 3
- Neoplasm Phase 3
- Neoplasm of mature B-cells Phase 2
- Primary central nervous system lymphoma Phase 3
- Relapsing-remitting multiple sclerosis Phase 2
- Secondary progressive multiple sclerosis Phase 3
- Systemic lupus erythematosus Phase 2
- Waldenstrom macroglobulinemia Phase 2
Other linked conditions (3)
- B-cell non-Hodgkin lymphoma
- Chronic lymphocytic leukemia/small lymphocytic lymphoma
- Neuromyelitis optica
Targets (1)
- BTK Tyrosine-protein kinase BTK inhibitor